Advertisement

Drugs

, Volume 67, Issue 1, pp 75–93 | Cite as

Ocular Adverse Effects Associated with Systemic Medications

Recognition and Management
  • Ricardo M. Santaella
  • Frederick W. Fraunfelder
Review Article

Abstract

This article reviews several retrospective case series and reported adverse events regarding common ocular adverse effects related to systemic therapy. It is not intended as a comprehensive summary of these well described adverse drug reactions, nor is it intended to cover the complete spectrum of all ocular adverse effects of systemic therapy. Many systemic drugs may produce ocular toxicity, including bisphosphonates, topiramate, vigabatrin, isotretinoin and other retinoids, amiodarone, ethambutol, chloroquine and hydroxychloroquine, tamoxifen, quetiapine, cyclo-oxygenase (COX)-2 inhibitors, erectile dysfunction agents and some herbal medications. For this review, the certainty of the adverse effect profile of each medication was evaluated according to the WHO Causality Assessment Guide.

A certain relationship has been established for pamidronate and alendronate as causes of scleritis, uveitis, conjunctivitis and blurred vision. Topiramate has been established as adversely causing symptoms consistent with acute angle-closure glaucoma, typically bilateral. Vigabatrin has been shown to cause bilateral irreversible visual field defects attributed to underlying medication-induced retinal pathology. Isotretinoin should be considered in the differential diagnosis of any patient with pseudotumour cerebri. Patients taking amiodarone and hydroxychloroquine should be monitored and screened regularly for development of optic neuropathy and maculopathy, respectively. Sildenafil has been reported to cause several changes in visual perception and is a possible, not yet certain, cause of anterior ischaemic optic neuropathy. Patients taking tamoxifen should also be monitored for development of dose-dependent maculopathy and decreased colour vision. COX-2 inhibitors should be included in the differential diagnosis of reversible conjunctivitis. Several herbal medications including canthaxanthine, chamomile, datura, Echinacea purpurea, Ginkgo biloba and liquorice have also been associated with several ocular adverse effects.

It is the role of all healthcare professionals to detect, treat and educate the public about adverse reactions to medications as they are an important health problem.

Keywords

Uveitis Pamidronate Intracranial Hypertension Isotretinoin Optic Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was supported in part by an unrestricted grant to Casey Eye Institute from Research to Prevent Blindness, New York, NY and by the National Registry of Drug-Induced Ocular Side Effects (www.eyedrugregistry.com). This report did not require approval by the OHSU Institutional Review Board. We would like to thank Genevieve Long for her assistance in the editing and modifications of this paper. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Bettman JW. Seven hundred medicolegal cases in ophthalmology. Ophthalmology 1990; 97: 1379–84PubMedGoogle Scholar
  2. 2.
    Brick DC. Medication errors result in costly claims for ophthalmologists. Surv Ophthalmol 1995; 40: 232–6PubMedCrossRefGoogle Scholar
  3. 3.
    Fraunfelder FT, Fraunfelder FW. Drug-induced ocular side effects. 5th rev. ed. Boston (MA): Butterworth-Heinemann, 2001Google Scholar
  4. 4.
    Chiou GCY. Ocular toxicology. 2nd ed. Philadelphia (PA): Taylor & Francis, 1999: 43–86, 225–354Google Scholar
  5. 5.
    Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of hte literature. Eye 2006 Apr; 20 (4): 407–16PubMedCrossRefGoogle Scholar
  6. 6.
    Edwards R, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93–102PubMedCrossRefGoogle Scholar
  7. 7.
    Fleish H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–44Google Scholar
  8. 8.
    Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf 1997; 17: 197–207Google Scholar
  9. 9.
    Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994; 118: 220–4PubMedGoogle Scholar
  10. 10.
    Fraunfelder FW, Fraunfelder FT. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003; 135: 219–22PubMedCrossRefGoogle Scholar
  11. 11.
    Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular side effects. N Engl J Med 2003; 348: 1187–8PubMedCrossRefGoogle Scholar
  12. 12.
    Foster CS, Forstet SL, Wilson LA. Mortality rate and rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology 1984; 91: 1253–63PubMedGoogle Scholar
  13. 13.
    Stewart GO, Stuckey BG, Ward LC. Iritis following intravenous pamidronate. Aust N Z J Med 1996; 26: 414–5PubMedCrossRefGoogle Scholar
  14. 14.
    Ghose K, Waterworth R, Trolove P. Uveitis associated with pamidronate. Aust N Z J Ophthalmol 1994; 24: 320Google Scholar
  15. 15.
    Des Grottes JM, Schrooyen M, Dumon JC. Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. Clin Rheumatol 1997; 16: 93–5PubMedCrossRefGoogle Scholar
  16. 16.
    Medical Economics Company. Physicians’ Desk Reference. 56th ed. Montvale (NJ): Medical Economics Company, 2002Google Scholar
  17. 17.
    Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–63PubMedCrossRefGoogle Scholar
  18. 18.
    Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis. Ann Rheum Dis 2003; 62: 378PubMedCrossRefGoogle Scholar
  19. 19.
    Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997; 61: 386–92PubMedCrossRefGoogle Scholar
  20. 20.
    Mbekeani JN, Slamovits TL, Schwartz BH, et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999; 117: 837–8PubMedGoogle Scholar
  21. 21.
    Malik AR, Campbell SH, Toma NM. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 2002; 86: 1443PubMedCrossRefGoogle Scholar
  22. 22.
    Siris ES. Bisphosphonates and iritis. Lancet 1993; 341: 436–7PubMedCrossRefGoogle Scholar
  23. 23.
    Vinas G, Olive A, Holgado S, et al. Episcleritis secondary to risedronate. Med Clin 2002 Apr 27; 118: 598–9Google Scholar
  24. 24.
    Watson PG. The nature and the treatment of scierai inflammation. Trans Ophthalmol Soc UK 1982; 102: 257–81PubMedGoogle Scholar
  25. 25.
    Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 2004 Jan; 111 (1): 109–11PubMedCrossRefGoogle Scholar
  26. 26.
    Thambi L, Kapcala LP, Chambers W, et al. Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Ophthalmol 2002 Aug; 120 (8): 1108PubMedCrossRefGoogle Scholar
  27. 27.
    Banta JT, Hoffman K, Budenz DL, et al. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001 Jul; 132: 112–4PubMedCrossRefGoogle Scholar
  28. 28.
    Bovino JA, Marcus FF. The mechanism of transient myopia induced by sulfonamide therapy. Am J Ophthalmol 1982 Jul; 94: 99–101PubMedGoogle Scholar
  29. 29.
    Chirls IA, Norris JW. Transient myopia associated with vaginal sulfanilamide suppositories. Am J Ophthalmol 1984 Jul 15; 98: 120PubMedCrossRefGoogle Scholar
  30. 30.
    Hook SR, Holladay JT, Prager TC, et al. Transient myopia induced by sulfonamides. Am J Ophthalmol 1986 Apr 15; 101: 495–6PubMedGoogle Scholar
  31. 31.
    Kimura R, Kasai M, Shoji K, et al. Swollen ciliary processes as an initial symptom in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1983 Mar; 95: 402PubMedGoogle Scholar
  32. 32.
    Ben-Menachem E. Vigabatrin. Epilepsia 1995; 36 Suppl. 2: S95–104PubMedCrossRefGoogle Scholar
  33. 33.
    Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia 1997 Aug; 38: 859–80PubMedCrossRefGoogle Scholar
  34. 34.
    Chiron C, Dulac O, Luna D, et al. Vigabatrin in infantile spasms. Lancet 1990 Feb 10; 335: 363–4PubMedCrossRefGoogle Scholar
  35. 35.
    Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 1999 Feb; 14: 71–4PubMedCrossRefGoogle Scholar
  36. 36.
    Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Clin Pharmacol 1989; 27: 3–11SCrossRefGoogle Scholar
  37. 37.
    Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional crossover study. Epilepsy Res 1996; 25: 257–62Google Scholar
  38. 38.
    Elke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180–1CrossRefGoogle Scholar
  39. 39.
    Wild JM, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40: 1784–94PubMedCrossRefGoogle Scholar
  40. 40.
    Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922–66PubMedCrossRefGoogle Scholar
  41. 41.
    Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin. Neurology 1999; 53: 2082–7PubMedCrossRefGoogle Scholar
  42. 42.
    Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792–8PubMedCrossRefGoogle Scholar
  43. 43.
    Harding GFA, Wild JM, Robertson KA, et al. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 2000; 55: 347–52PubMedCrossRefGoogle Scholar
  44. 44.
    Gross-Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000; 48: 60–4PubMedCrossRefGoogle Scholar
  45. 45.
    Mustafa BA. Diversity of GABA receptors in the vertebrate outer retina. Trends Neurosci 1995; 85: 118–20Google Scholar
  46. 46.
    Pow DV, Baldridge W, Crook DK. Activity-dependent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy. Neuroscience 1996; 73: 1129–43PubMedCrossRefGoogle Scholar
  47. 47.
    Butler WH. The neuropathology of vigabatrin. Epilepsia 1989; 30 Suppl. 3: S15–17PubMedCrossRefGoogle Scholar
  48. 48.
    Neal MJ, Cunningham JR, Shah MA, et al. Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci Lett 1989; 89: 29–32CrossRefGoogle Scholar
  49. 49.
    Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792–8PubMedCrossRefGoogle Scholar
  50. 50.
    Kaufman KR, Lepore FE, Keyser BJ. Visual fields and tiagabine: a quandary. Seizure 2001; 10: 525–9PubMedCrossRefGoogle Scholar
  51. 51.
    Krauss G, Johnson M, Sheth S, et al. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatr 2003; 74: 339–43PubMedCrossRefGoogle Scholar
  52. 52.
    Nousiainen I, Mäntyjärvi M, Kälviäinen R. Visual function in patients treated with the GABAergic anticonvulsant drug tiagabine. Clin Drug Invest 2000; 20: 393–400CrossRefGoogle Scholar
  53. 53.
    Sorri I, Kalviainen R, Mantyjarvi M. Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy. Epilepsy Res 2005 Dec; 67 (3): 101–7PubMedCrossRefGoogle Scholar
  54. 54.
    Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology 2004 Jun; 111 (6): 1248–50PubMedCrossRefGoogle Scholar
  55. 55.
    Fraunfelder FT, Fraunfelder FW. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001; 132 (3): 299–305PubMedCrossRefGoogle Scholar
  56. 56.
    Cchroeter T, Lanvers C, Herding H, et al. Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia. Med Pediatr Oncol 2000; 34: 284–6CrossRefGoogle Scholar
  57. 57.
    Sano F, Tsuji K, Kunika N, et al. Pseudotumor cerebri in a patient with acute promyelocytic leukemia during treatment with all-trans-retinoic acid. Intern Med 1998; 37 (6): 546–9PubMedCrossRefGoogle Scholar
  58. 58.
    Tiamkao S, Sirijirachai C. Pseudotumor cerebri caused by all-trans-retinoic acid: a case report. J Med Assoc Thai 2000; 83 (11): 1420–3PubMedGoogle Scholar
  59. 59.
    Fraunfelder FW, Fraunfelder FT. Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol 2004 Sep; 24 (3): 214–6PubMedCrossRefGoogle Scholar
  60. 60.
    Guirgis MF, Lueder GT. Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management. J AAPOS 2003; 7 (6): 432–4PubMedCrossRefGoogle Scholar
  61. 61.
    Morrice G, Havener WH, Kapetansky F. Vitamin A intoxication as a cause of pseudotumor cerebri. JAMA 1960; 173: 1802–5PubMedCrossRefGoogle Scholar
  62. 62.
    Jacobson DM, Berg R, Wall M, et al. Serum vitamin A concentration is elevated in idiopathic intracranial hypertension. Neurology 1999; 53 (5): 1114–8PubMedCrossRefGoogle Scholar
  63. 63.
    Visani G, Manfroi S, Tosi P, et al. All-trans-retinoic acid and pseudotumor cerebri. Leuk Lymphoma 1996; 23: 437–42PubMedCrossRefGoogle Scholar
  64. 64.
    Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis 1988; 42: 399–400PubMedGoogle Scholar
  65. 65.
    Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 1995; 55 (3): 165–8PubMedGoogle Scholar
  66. 66.
    Donahue SP. Recurrence of idiopathic intracranial hypertension after weight loss: the carrot craver. Am J Ophthalmol 2000; 130 (6): 850–1PubMedCrossRefGoogle Scholar
  67. 67.
    Hoffner SE, Kallenius G, Beezer AE, et al. Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex. Acta Leprol 1989; 7 Suppl. 1: 195–9Google Scholar
  68. 68.
    Sadun AA. Metabolic optic neuropathies. Semin Ophthalmol 2002; 17 (1): 29–32PubMedCrossRefGoogle Scholar
  69. 69.
    Kaimbo WK, Bifuko ZA, Longo MB, et al. Color vision in 42 Congolese patients with tuberculosis receiving ethambutol treatment. Bull Soc Belge Ophtalmol 2002; 284: 57–61PubMedGoogle Scholar
  70. 70.
    Karmon G. Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. Ann Ophthalmol 1979; 11: 1013PubMedGoogle Scholar
  71. 71.
    Kass I, Mandel W. Isoniazid as a cause of optic neuritis and atrophy. JAMA 1957; 164: 1740–3CrossRefGoogle Scholar
  72. 72.
    Kozak SF, Inderlied CB, Hsu HY, et al. The role of copper on ethambutol’s antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagn Microbiol Infect Dis 1998; 30: 83–7PubMedCrossRefGoogle Scholar
  73. 73.
    Sadun AA. Metabolic optic neuropathies. Semin Ophthalmol 2002 17 (1): 29–32PubMedCrossRefGoogle Scholar
  74. 74.
    Feiner LA, Younge BR, Kazmier FJ, et al. Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987; 62: 702–17PubMedCrossRefGoogle Scholar
  75. 75.
    Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999; 127 (5): 610–2PubMedCrossRefGoogle Scholar
  76. 76.
    Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998; 42: 360–6PubMedCrossRefGoogle Scholar
  77. 77.
    Marmor MF, Carr RE, Easterbrook E, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377–82PubMedCrossRefGoogle Scholar
  78. 78.
    Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4 aminoquinoline retinopathy: is retinal toxicity by chloriquinine and hydroxychlorquine related to Stargardt disease? Am J Ophthalmol 2001 Jun; 131 (6): 761–6PubMedCrossRefGoogle Scholar
  79. 79.
    Fraunfelder FW. Visual side effects associated with erectile dysfunction agents. Am J Ophthalmol 2005 Oct; 140 (4): 723–4PubMedCrossRefGoogle Scholar
  80. 80.
    Reivich M, Holling HE, Roberts B, et al. Reversal of blood flow through the vertebral artery and its effect on cerebral circulation. N Engl J Med 1961 Nov 2; 265: 878–85PubMedCrossRefGoogle Scholar
  81. 81.
    Laties AM, Fraunfelder FT. Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthalmol Soc 1999; 97: 115–28PubMedGoogle Scholar
  82. 82.
    Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125: 493–501PubMedCrossRefGoogle Scholar
  83. 83.
    Gorin MB, Costantino JP, Kulacoglu DN, et al. Is tamoxifen a risk factor for retinal vaso-occlusive disease? Retina 2005; 25: 523–6PubMedCrossRefGoogle Scholar
  84. 84.
    Fraunfelder FW, Solomon J, Mehelas TJ. Ocular side effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol 2006; 124: 277–279PubMedCrossRefGoogle Scholar
  85. 85.
    Coulter DM, Clark DWJ, Savage RL. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 2003; 327: 1214–5PubMedCrossRefGoogle Scholar
  86. 86.
    Haefliger IO, Meyer P, Flammer J, et al. The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology. Surv Ophthalmol 1994; 39: 123–32PubMedCrossRefGoogle Scholar
  87. 87.
    Tullio CJ. Ibuprofen-induced visual disturbance. Am J Hosp Pharm 1981; 38: 1362PubMedGoogle Scholar
  88. 88.
    Nicastro NJ. Visual disturbances associated with over-the-counter ibuprofen in three patients. Ann Ophthalmol 1989; 21: 447–50PubMedGoogle Scholar
  89. 89.
    Bovino JA, Marcus FF. The mechanism of transient myopia induced by sulfonamide therapy. Am J Ophthalmol 1982; 94: 99–101PubMedGoogle Scholar
  90. 90.
    Lutz EG. Allergic conjunctivitis due to diazepam. Am J Psych 1975; 132 (5): 548Google Scholar
  91. 91.
    Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 1995; 79: 54–6PubMedCrossRefGoogle Scholar
  92. 92.
    Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol 1973; 76: 500–10PubMedGoogle Scholar
  93. 93.
    Jampol LM. Niacin maculopathy. Ophthalmology 1988; 95: 1704–5PubMedGoogle Scholar
  94. 94.
    Fraunfelder FW. Ocular side effects associated with dietary supplements and herbal medicines. Drugs Today 2005; 41 (8): 537–45PubMedCrossRefGoogle Scholar
  95. 95.
    Physicians’ Desk Reference for herbal medicines. 2nd rev. ed. Montvale (NJ): Thomson Healthcare, 2004Google Scholar
  96. 96.
    Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998 Nov 11; 289 (18): 1569–75CrossRefGoogle Scholar
  97. 97.
    Fraunfelder FW. Ocular side effects from herbal medicines and nutritional supplements. Am J Ophthalmol 2004 Oct; 138 (4): 639–47PubMedCrossRefGoogle Scholar
  98. 98.
    Espaillat A. Canthaxanthine retinopathy. Arch Ophthalmol 1999; 113: 412–3Google Scholar
  99. 99.
    Subiza J. Allergic conjunctivitis to chamomile tea. Ann Allergy Asthma Immunol 1990; 65: 127–32Google Scholar
  100. 100.
    Blumenthal M, editor. The complete German Commission E monographs therapeutic guide to herbal medicines. Austin (TX): American Botanical Council, 1998Google Scholar
  101. 101.
    Grimm W, Muller H. A randomized controlled trial of the effect of fluid extract of echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 1999 Feb; 106: 138–43PubMedCrossRefGoogle Scholar
  102. 102.
    Dobbins KR, Saul RF. Transient visual loss after licorice ingestion. J Neurophthalmol 2000 Mar; 20: 38–41CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Ricardo M. Santaella
    • 1
  • Frederick W. Fraunfelder
    • 1
  1. 1.Casey Eye InstituteOregon Health & Science UniversityPortlandUSA

Personalised recommendations